The BSCC New Frontiers in Healthcare Conference
Advanced digital health care providers segmentation
Elevating customer understanding leveraging AI
Our advanced segmentation approach enables to define data-driven HCP segments by leveraging AI and machine learning algorithms. We display a detailed use case that describes how we have helped biopharma companies leverage data and AI to build differentiated and actionable HCP segments.
Commercial Operations in Life Sciences
Driving simplification and efficiency across Commercial Operations
Digital transformation of commercial operations has transitioned from a “nice-to-have” enabler to a “must-have” capability, making it critical for Life Science companies to evaluate how digital tools will deliver customer centricity and service innovation across the commercial operations value chain
Measuring the return from pharmaceutical innovation 2021
Our latest report looks at the current state of R&D returns for 15 leading biopharma companies, the impact of the pandemic on R&D pipelines during 2021 and how this has expedited the adoption of digital solutions and impacted the IRR.
Take Heart and Stop the Silent Killer
Prevent death from Atherosclerotic Cardiovascular Disease (ASCVD)
This report looks at the impact of CVD challenges, focused on ASCVD and the silent killer of heart attacks and stroke. There is significant opportunity for improved CVD secondary prevention care in the Latin America region, specifically looking at: Argentina, Brazil, Chile, Colombia, and Mexico.
Intelligent drug launch and commercial
Optimising value through AI
This is the fifth report in our Intelligent biopharma series, which explores the current and future potential of artificial intelligence (AI) across the biopharma value chain. This report focuses on how companies can use AI to improve drug launches and their commercial models.
Predicting the future of healthcare and life sciences in 2025
The future unmasked
What does the future hold for the life sciences and healthcare industry? Our latest predictions report looks ahead to the year 2025 to help you see what’s coming and to keep your organisation moving forward.
How can virtual health help expand capacity in the wake of an anticipated COVID-19 surge?
When faced with a health crisis like Covid-19, social distancing can take some of the strain off healthcare providers at the front lines. But when that’s not enough, innovations like virtual healthcare can help increase capacity, reduce the rate of infection, and treat non-urgent cases.
Securing trust in the global COVID-19 supply chain
From development and delivery to acceptance and administration
COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products.
Forging the links across the value chain
The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies.
COVID-19: Shaping the future regulation of emergency medical equipment supply
The COVID-19 pandemic has disrupted everyone’s daily lives and touched every industry across the world. While many countries had influenza and other pandemic preparedness plans in place prior to COVID-19, no one was fully prepared for the speed and indiscriminate spread of the disease.
Accelerating the Future of Health
COVID-19 responses from the health ecosystem
Responding to COVID-19 is an enormous challenge for companies of all sizes and in all sectors, not least life sciences. The pandemic is affecting the pharmaceutical ecosystem and highlighting the importance of health technology economically, politically, and socially.
2022 Global Life Sciences Outlook
Digitalization at scale: Delivering on the promise of science
Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. How will life sciences companies continue to respond and what areas can they build resiliency going forward?